Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas

Inclusion Criteria: * Patients with histologically confirmed L-sarcomas (leiomyosarcoma and liposarcoma) * Measurable disease according to RECIST 1.1 * Any treatment line except adjuvant setting: evidence of primary metastatic situation or disease progression within the last 6 months (based on RECIST 1.1) in computed tomography or magnetic resonance imaging * Any prior treatment possible * Age \>= 18 years * WHO PS =\< 1 * Effective contraception during study medication and up to 3 months from treatment discontinuation * Signed informed consent form Exclusion Criteria: * Surgical intervention \< 4 weeks * Pregnancy or lactation * Known allergic reaction to trabectedin or gemcitabine or one of their components * The following laboratory values: Absolute neutrophil count \< 1.5 x 103/mm3 Platelets \< 100.000/mm3 Hb \< 9 g/dL Serum creatinine \>= 2.5 mg/dl SGOT and/or SGPT and/or alkaline phosphatase and/or CPK \> 2.5 x ULN Total bilirubin \> 1 x ULN except in the case of Gilbert's syndrome * Participation in another study (four weeks before and during the study) * Prior malignancy apart from completely resected basal cell carcinoma of the skin or carcinoma in situ of the uterine cervix